Understanding how platelets contribute to liver disease caused by alcohol.
The role of platelets in the pathogenesis of alcohol-associated liver disease
This study is looking at how platelets, which are tiny cells in your blood, affect liver problems caused by alcohol, with the goal of finding new ways to help people who are dealing with this issue.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10894211 on NIH RePORTER |
What this research studies
This research investigates the role of platelets in alcohol-associated liver disease (ALO), which is a growing health concern in the U.S. The study aims to uncover how platelets contribute to liver inflammation, fibrosis, and injury in patients with ALO. By examining the interactions between platelets and liver cells, the researchers hope to identify new therapeutic targets that could improve treatment outcomes for individuals suffering from this condition. The research involves both laboratory experiments and in vivo studies to explore the mechanisms at play.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with alcohol-associated liver disease, particularly those experiencing liver inflammation or fibrosis.
Not a fit: Patients with liver disease not related to alcohol consumption or those with advanced liver disease requiring immediate intervention may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the management and outcomes of alcohol-associated liver disease.
How similar studies have performed: While the role of platelets in liver disease is recognized, this specific investigation into their mechanistic role in alcohol-associated liver disease is relatively novel and has not been extensively tested.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Mcconnell, Matthew Joseph — Yale University
- Study coordinator: Mcconnell, Matthew Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.